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Drug therapy is frequently given to neonates via their endotracheal tube.  The majority of drugs are given by aerosolisation, but some are given as a liquid bolus (eg surfactant).  The aim of this review is to describe whether the benefits of administering drug therapy via an endotracheal tube have been robustly proven, as well as highlighting the challenges, limitations and indeed potential hazards. In addition, we have included some information on alternative airway delivery routes (see the surfactant section) that is rather than via the endotracheal tube. 

Aerosolisation
Aerosol entrainment can be achieved by placing the nebuliser either within the inspiratory arm of the circuit or introducing the aerosol between the patient interface and the “Y” connector.  The former position is recommended for metered dose inhalers (MDIs) and vibrating mesh and jet nebulisers, whereas the latter position is recommended for MDIs with a spacer device.[1]  Aerosol delivery to the lower airways is small, between one and ten percent in intubated neonates.[2]  This is due to their high respiratory rate, low tidal volumes and small airway diameters [3, 4] (Table 1). A further influencing factor is the mode of ventilation, delivery can be affected by the inspiratory time and inspiratory flow pattern.  Increasing nebuliser air flow leads to increased aerosol impaction in the upper airways with concomitant decreased deposition in the lungs.  Synchronisation of nebuliser aeration with the patient’s inspiratory efforts reduces the amount of drug lost in expiration, achieving this in neonates, however, is challenging because of their rapid respiratory rate and short inspiratory time.  Aerosol particle size is also important, small particles with short inflation times and low inspiratory flows can result in significant exhalation losses.  The particles, however, need to be small enough to bypass the interface without much impaction.  Aerosolised drugs, if exhaled by the patient, can contaminate the positive end expiratory pressure (PEEP) valve increasing resistance.  There are relatively few studies of deposition in neonates, as radio-labelled drugs cannot be used.[5]  Much more evidence is required to determine the optimum aerosol delivery system.  

Oxygen
Supplementary oxygen is the most frequently used therapy delivered by the endotracheal tube.  High concentrations, however, can cause toxicity, resulting in inflammation and fibrosis.[6, 7]. The most appropriate target oxygen saturation levels have been an area of uncertainty and hence investigated in a number of RCTs.  An RCT which included 358 infants born at less than 30 weeks of gestational age demonstrated no significant differences in growth, neurodevelopmental abnormalities at 12 months or mortality between those randomised to 91-94% or 95-98% oxygen saturation targets.[8]  The high saturation target group predictably required longer hospitalisation and more required supplementary oxygen at 36 weeks PMA and/or home supplementary oxygen.[8].  Meta-analysis of five RCTs demonstrated lower oxygen saturation targets reduced the incidence and severity of retinopathy of prematurity (ROP) without increasing mortality.[9]  Subsequenty, RCTs and a meta-analysis which included 4,911 infants of less than 28 weeks of gestational age who were randomised on the first day after birth to 85-89% or 91-95% oxygen saturation target levels was reported.[10]  The infants in the low saturation group had a higher mortality and occurrence of necrotising enterocolitis (NEC).[10]  Thus, most recommend oxygen saturations of between 91 and 95% in the acute phase of the respiratory illness. 

Surfactant
Surfactant replacement therapy is an important part of standard care for prematurely born infants, its efficacy has been robustly demonstrated in multicentre, randomised controlled trials (RCTs) and meta-analyses.[11-13] Recent guidelines [14, 15] recommend early, selective natural surfactant for prematurely born infants.





Inhaled Nitric Oxide 
Inhaled nitric oxide (iNO) reduces the combined outcome of need for extracorporeal membrane oxygenation (ECMO) or death (relative risk (RR) 0.65, 95% CI 0.54-0.75) in infants born at or near term. This was as a result of the reduction in ECMO requirement.[17] Oxygenation improved in approximately 50% of infants.[17]  In prematurely born infants, a systematic review of 14 RCTs put the trials into three groups: entry in the first three days based on oxygenation criteria, routine use in prematurely born infants with pulmonary disease and late enrolment based on an increased risk of BPD. Neither the nine trials of early rescue treatment based on oxygenation criteria or the three studies of routine use in infants with pulmonary disease demonstrated significant reductions in BPD or mortality.  Later treatment in infants at risk of BPD (two trials) was not associated with a significant reduction in BPD.[18] An individual patient data meta-analysis which included results from 3298 infants did not find a significant improvement in mortality or BPD.[19] It is possible that the use of higher doses (>5ppm) might be associated with improved outcomes, but this needs further investigation.[19]  Current recommendations [20] are that iNO should not be used in prematurely born infants to prevent BPD, but can be beneficial for those with severe hypoxaemia that is, primarily due to persistent pulmonary hypertension of the newborn (PPHN) rather than parenchymal lung disease, particularly if it is  associated with prolonged rupture of membranes and oligohydramnios. 

Prostacycline 





Systemically administered corticosteroids reduce BPD and facilitate extubation, but have numerous side-effects.  Administering corticosteroids by the inhaled route and reducing the systemic side-effects is then an attractive option.  Meta-analysis of three trials which compared the efficacy of inhaled to systemic corticosteroids in ventilator dependent infants with a birth weight < 1500 grams or gestational age < 32 weeks and a postnatal age greater than two weeks demonstrated no significant difference in effectiveness, that is reduction in BPD or side-effects.[25]  The authors concluded that neither inhaled or systemic steroids should be recommended as standard therapy for ventilated, prematurely born infants. A meta-analysis of eight trials including in total 232 infants evaluated the efficacy of inhaled steroid administration after the first week from birth in preterm infants at high risk of developing BPD. It demonstrated inhaled steroids did not reduce the separate or combined outcomes of death or BPD.  Furthermore, inhaled corticosteroids did not impact on failure to extubate or the total duration of mechanical ventilation or oxygen dependency.[26]  

The Neonatal European Study of Inhaled Steroids (NEUROSIS) trial examined the effects of inhaled budesonide administered in the first 24 hours after birth versus placebo in 863 infants born at 23 to 27 weeks gestation who required any form of positive-pressure support.[27]  They received the intervention until they no longer required supplementary oxygen or positive pressure support or reached a PMA of 32 weeks. A significant reduction in the rate of BPD (RR 0.74, 95% CI 0.60-0.92) was demonstrated in the intervention group.[27]  In addition, significant reductions in infants requiring surgical closure of a patent ductus arteriosus (PDA) or reintubation also were noted in the intervention group.  Unfortunately, there was a trend towards increased mortality (16.9% versus 13.6%).[27]  It was suggested that the increased mortality in the budesonide group could be due to chance or a higher incidence of pneumonia.[28]  The reported rates of sepsis or infection, however, did not differ between the groups in the RCT.[27]
 
A promising intervention is delivering in-tracheal instillation of budesonide using surfactant as a vehicle.  A pilot study of 116 very low birth weight infants (VLBW) who had severe radiographic respiratory distress syndrome requiring mechanical ventilation and an inspired oxygen concentration of at least 60% was performed.  They were randomised to budesonide suspension with surfactant or surfactant alone.[29]  The proportion of infants who survived without BPD was significantly higher in the treatment group and no clinically significant adverse effects were reported.[29]  Follow up of the participants when they were between two to three years of age demonstrated no significant differences in the physical growth or the results of neurological examination; no sample size calculation, however, was given.[30]  A multicentre RCT was then performed by the same group and included 265 infants with severe RDS.  The sample size was calculated to detect a difference in the BPD rate of 60% in the control group and 40% in the intervention arm.  The intervention group had a lower incidence of BPD or death (RR 0.58, 95% CI 0.44-0.77), the number needed to treat was 4.1.[31]  The incidence of BPD or death in the control arm, however, was 66% and it would be interesting to determine if similar results were obtained in units with a higher rate of survival without BPD. Small RCTs of infants with meconium aspiration syndrome have suggested that inhaled corticosteroids may be beneficial [32-34], but this too needs testing in RCTs appropriately powered to assess clinically meaningful results. 

Clara cell 10-kD protein 
Non-ciliated, bronchial lung Clara cells produce Clara cell 1b-kD protein (CC10), a small anti-inflammatory protein which is deficient in prematurely born infants.[35] In a small RCT of 22 infants, the efficacy of one dose of intra-tracheal recombinant human (rh) CC10 at a low (1mg/kg) or a high dose (5mg/kg) following surfactant administration were compared to placebo.[36] A significant decrease in neutrophils and a tendency towards reduced interleukin-6 levels were noted in the rhCC10 groups.[36]  The higher compared to the lower dose was associated with a significant increase in days of mechanical ventilation.[37] Currently there is insufficient evidence to determine the role of rhCC10 in clinical practice.[37]

Pentoxifylline
Pentoxifylline is a xanthine derivative that has been shown to reduce circulating levels of TNF-α and cytokines in neonates. A RCT including 100 infants was performed to determine if nebulised pentoxifylline versus placebo reduced BPD.  No significant effect on BPD at 36 weeks PMA or death prior to 36 weeks PMA was demonstrated.[38]

Superoxide dismutase 
Superoxide dismutase is an endogenous anti-oxidant enzyme.  Administration of recombinant human CuZnSOD was investigated in a RCT of 202 preterm infants.  There were no significant differences in mortality or the incidence of BPD, but at a median of one year of follow-up in those born less than 27 weeks of gestation, significantly fewer of the treated group had emergency department visits and subsequent hospitalisation.[39]  Overall, more of the placebo group had repeated episodes of wheeze or other respiratory illnesses severe enough to require anti-asthma medications.[39]  Surprisingly, these promising results have not led to further studies assessing this treatment.

Bronchodilators
A Cochrane review identified only one prospective RCT which fulfilled the inclusion criteria that clinical outcomes should be reported.[40]  One study included 173 infants of gestational age less than 31 weeks who required mechanical ventilation on the tenth day and were randomised to receive inhaled salbutamol, beclomethasone and salbutamol, beclomethasone, or placebo for 28 days.[41] Salbutamol, beclamethasone or a combination of the two therapies compared to placebo did not lead to a significant reduction in mortality, the incidence of BPD or the durations of assisted ventilation or oxygen supplementation.[41]  In another study, as the administration of salbutamol, a β-agonist could increase lung fluid absorption, the hypothesis was tested that salbutamol administration would decrease the failure rate of the INSURE technique.  Although no significant differences were found in the INSURE failure rate or the duration of nCPAP, the duration of hospitalisation was shorter in the salbutamol group.[42] A retrospective cohort study of infants less than 29 weeks of gestation from the Paediatric Health Information System database identified 33% of 1429 infants with BPD received bronchodilators.  Longer duration of mechanical ventilation increased the odds of receiving a bronchodilator (OR 19.6, 11 to 34.6) at > 5 days.  There was, however, marked between hospital variation in use.[43]  On current evidence, inhaled bronchodilators should be restricted to neonates with wheeze that is compromising their gas exchange and only continued when shown to be associated with clinically important benefits. 

Diuretics




Ventilator-associated pneumonia (VAP) is an important problem in intubated neonates.  Colistin disrupts the outer membrane of bacteria leading to cell death. It was used in the 1960s, but caused neurotoxicity and nephrotoxicity.  There have now been reports of aerosolised colistin, as an adjunctive therapy or monotherapy in term or prematurely born infants with VAP, leading to eradication of bacteria from sputum. None of the adverse effects of systemic colistin were highlighted, but the reports were of cases or small series.[44,45] Randomised controlled trials are required to confirm or otherwise these preliminary results. 

Mucolytics




Heliox, a mixture of the inert gas helium and oxygen, has a low density which reduces air flow resistance. In a pilot study of 15 infants with severe BPD,  heliox administration for sixty minutes resulted in a significant increase in tidal volume and compliance and a significant decrease in their OI.[49]   In another study, heliox administration in ten infants who were studied before extubation was associated with a reduction in their work of breathing.[50]  A pilot study of eight ventilated neonates with MAS demonstrated that mechanical ventilation when heliox was administered was associated with a significant lower FiO2 and alveolar-arterial oxygen tension difference.[51] Randomised trials are required to more robustly determine the efficacy of this therapy.

Xenon
Use of the anaesthetic gas xenon during therapeutic hypothermia in infants with  hypoxic ischaemic encephalopathy (HIE) had been shown in preclinical trials to improve neuroprotection.  In a clinical feasibility trial, cooled newborns who were less than 18 hours of age were entered into a single arm, escalation study if they required less than 35% oxygen.  Xenon duration was increased stepwise from three to 18 hours in 14 subjects.  No adverse respiratory or cardiovascular effects were reported.[52]  Seven of eleven survivors had mental and physical developmental scores > 70 at follow up.  The total body hypothermia plus Xenon (TOBY-Xe) trial randomised 92 infants with moderate to severe HIE to cooling alone or cooling in combination with 30% xenon.[53] Magnetic resonance assessments highlighted that xenon did not have additional neuroprotective effects compared with induction of hypothermia alone after birth asphyxia.  Two adverse events occurred in desaturation the xenon group, transient and subcutaneous fat necrosis during the MRI.[53]  Whether a higher level of xenon (50%) may be additive is currently being investigated.[54]

Mesenchymal stem cells
There are promising early results of stem cells impacting on BPD development in animal models.  Hyperoxia induced BPD in neonatal rats was associated with decreased circulating and resident mesenchymal stem cells (MSC).[55] Administration of bone marrow derived MSCs or multipotent stromal cells prevented the compromised alveolar and vascular development.[55] In a rat model, hyperoxia exposure led to air space enlargement, loss of lung capillaries and low expression of VEGF and eNOS.  Transplanted endothelial progenitor cells, when combined with inhaled nitric oxide (iNO), resulted in improved alveolarisation, microvessel density and upregulation of VEGF and eNOS proteins.[56]   Bronchioalveolar stem cells (BASCs) are an adult lung stem cell population capable of self-renewal and differentiation in culture.[57] Treatment of neonatal hyperoxia-exposed mice with MSC and MSC conditional media resulted in an increase in BACs, which may then play a role in lung injury repair in BPD.[57]  A phase 1 dose escalation trial has been undertaken to assess the safety and feasibility of a single, intratracheal transplantation of human umbilical cord blood (hUCB) derived MSCs in preterm infants at high risk of BPD.[58]  Nine infants with a mean gestational age of 25.3 weeks were included in the trial.  Compared to historical controls, BPD severity was lower in the transplant recipients.[58]  MSCs pose a theoretical risk of promoting tumour growth and malignant changes, thus long term follow up  is required.  In a follow up study of up to sixty months post MSC transplantation of 1012 adult and paediatric patients with mixed pathologies, however, there was no increased incidence of death, malignancy, infection or toxicity.[59] The promising results in neonates requires further investigation in appropriately designed trials with long term follow up.   

Conclusions
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Table 2:  Efficacious inhaled drugs in intubated neonates

Proven	Unproven	More evidence is required
Surfactant	Diuretics	Corticosteroids (inhaled)
Nitric oxide	Bronchodilators	Prostacycline
	Mucolytics	Budesonide with surfactant
		rhCC10
		Pentoxyfilline
		Colistin
		Heliox
		Superoxide dismutase
		Xenon
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